Fenbendazole for humans cancer
The drug fenbendazole (FZ) is an animal anthelmintic that has broad antiparasitic activity against ascarids, whipworms, hookworms, and a single species of tapeworm. It has also been shown to have anti-tumor effects in laboratory studies. FZ works by interfering with the formation of microtubules, a protein scaffold that gives cells their shape and structure.

A recent viral social media post claimed that a cancer patient had cured her own disease by self-administering fenbendazole, an animal anthelmintic. This case is intriguing, but the patient’s story must be interpreted carefully. The anecdotal report should be interpreted cautiously, because there isn’t enough evidence to show that fenbendazole can cure cancer in humans. The patient’s anecdotal experience may have been caused by other factors not addressed in this article, such as the conventional cancer treatments she received. In addition, fenbendazole hasn’t been shown to prevent cancer recurrence in patients.

This article focuses on the mechanisms by which fenbendazole triggers ferroptosis in colorectal cancer cells, and its effects on p53, SLC7A11, GPX4, and autophagy. The results suggest that fenbendazole induces apoptosis through a GPX4-dependent mechanism and that it increases DAMP, resulting in synergistic apoptosis and ferroptosis.

Currently, fenbendazole is available as a prescription-only medication in the US to treat gastrointestinal parasites. It is not approved for use in human cancer treatment. However, anthelmintics are being studied as potential cancer treatments, and research on this is ongoing. Until a peer-reviewed study finds sufficient evidence that fenbendazole can treat cancer in humans, doctors should advise patients to only use established therapies. fenbendazole for humans cancer